Chemomab Therapeutics (CMMB) said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.
Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.
Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.
Price: 1.17, Change: -0.03, Percent Change: -2.50
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.